- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the efficacy of the combination of ridaforolimus and bicalutamide compared to placebo and bicalutamide by PSA decline within 12 weeks, a surrogate measurement of overall survival efficacy in prostate cancer therapy trials. To determine the safety and tolerability of ridaforolimus when combined with bicalutamide.
Inclusion criteria
- metastatic prostate cancer